{"id":603,"date":"2026-07-22T09:46:33","date_gmt":"2026-07-22T09:46:33","guid":{"rendered":"https:\/\/www.vaultinsider.top\/?p=603"},"modified":"2026-07-22T09:46:33","modified_gmt":"2026-07-22T09:46:33","slug":"novo-nordisk-sues-eli-lilly-over-weight-loss-drug-comparison-ads","status":"publish","type":"post","link":"https:\/\/www.vaultinsider.top\/?p=603","title":{"rendered":"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads"},"content":{"rendered":"<p><\/p>\n<div><!----> <!----> <\/p>\n<div class=\"featured featured-video video-ct\">\n<div class=\"contain\">\n<div class=\"info\">\n<div class=\"caption\">\n<p>Check out what&#8217;s clicking on FoxBusiness.com.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>Novo Nordisk sued Eli Lilly on Tuesday, accusing its rival of misleading consumers by claiming Lilly\u2019s drugs work better than Novo\u2019s competing treatments.<\/p>\n<p>The lawsuit, filed in federal court in New Jersey, argues that Lilly\u2019s ads for Zepbound and Mounjaro compared the highest doses of its drugs with lower doses of Novo\u2019s Wegovy and Ozempic. Novo said the ads rely on &#8220;outdated&#8221; trial data, according to Reuters.<\/p>\n<p>&#8220;The ads are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk\u2019s medicines,&#8221; Novo said in its complaint.<\/p>\n<p><strong>TOM BRADY TEAMS WITH DIGITAL HEALTH FIRM EMED TO EXPAND GLP-1 WEIGHT LOSS MEDICATION ACCESS<\/strong><\/p>\n<div class=\"inline image-ct\">\n<div class=\"m\"><picture><source media=\"(max-width: 767px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/343\/192\/ozempic-pen-shot.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/686\/384\/ozempic-pen-shot.jpg?ve=1&amp;tl=1 2x\"><source media=\"(min-width: 768px) and (max-width: 1023px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/672\/378\/ozempic-pen-shot.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/1344\/756\/ozempic-pen-shot.jpg?ve=1&amp;tl=1 2x\"><source media=\"(min-width: 1024px) and (max-width: 1279px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/931\/523\/ozempic-pen-shot.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/1862\/1046\/ozempic-pen-shot.jpg?ve=1&amp;tl=1 2x\"><source media=\"(min-width: 1280px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/720\/405\/ozempic-pen-shot.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/1440\/810\/ozempic-pen-shot.jpg?ve=1&amp;tl=1 2x\"><img decoding=\"async\" src=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/931\/523\/ozempic-pen-shot.jpg?ve=1&amp;tl=1\" alt=\"A photo illustration of Ozempic pen\"\/><\/source><\/source><\/source><\/source><\/picture><\/div>\n<div class=\"caption\">\n<p><span>A photo illustration shows an Ozempic injection pen in London on June 17, 2026. The lawsuit argues that Lilly\u2019s ads for Zepbound and Mounjaro compared the highest doses of its drugs with lower doses of Novo\u2019s Wegovy and Ozempic.\u00a0<\/span><span> (Peter Dazeley\/Getty Images \/ Getty Images)<\/span><\/p>\n<\/div>\n<\/div>\n<p>Meanwhile, Lilly rejected the claims and said its ads are based on its SURMOUNT-5 trial, completed in 2024, which compared patients taking 10 mg or 15 mg of Zepbound with those taking 1.7 mg or 2.4 mg of Wegovy.<\/p>\n<p>The FDA approved a higher 7.2 mg dose of Wegovy in March, Reuters reported.<\/p>\n<p>&#8220;The gold standard for comparing medicines is a robustly designed, well-conducted head-to-head clinical trial \u2014 like SURMOUNT-5, which remains the only head-to-head, randomized clinical trial directly comparing tirzepatide and semaglutide in weight management,&#8221; a Lilly spokesperson told FOX Business in an email.<\/p>\n<p><strong>AMERICANS PAYING LESS AS TRUMP DRUG PRICING PUSH SLASHES GLP-1, FERTILITY MEDICINE COSTS, OFFICIAL SAYS<\/strong><\/p>\n<div class=\"inline image-ct\">\n<div class=\"m\"><picture><source media=\"(max-width: 767px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/343\/192\/zepbound-injection-shot.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/686\/384\/zepbound-injection-shot.jpg?ve=1&amp;tl=1 2x\"><source media=\"(min-width: 768px) and (max-width: 1023px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/672\/378\/zepbound-injection-shot.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/1344\/756\/zepbound-injection-shot.jpg?ve=1&amp;tl=1 2x\"><source media=\"(min-width: 1024px) and (max-width: 1279px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/931\/523\/zepbound-injection-shot.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/1862\/1046\/zepbound-injection-shot.jpg?ve=1&amp;tl=1 2x\"><source media=\"(min-width: 1280px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/720\/405\/zepbound-injection-shot.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/1440\/810\/zepbound-injection-shot.jpg?ve=1&amp;tl=1 2x\"><img decoding=\"async\" src=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/931\/523\/zepbound-injection-shot.jpg?ve=1&amp;tl=1\" alt=\"photo illustration of Zepbound with instruction sheet on a white background. It is an injectable medication used for chronic weight management\"\/><\/source><\/source><\/source><\/source><\/picture><\/div>\n<div class=\"caption\">\n<p><span>A photo illustration shows a Zepbound injection pen and instruction sheet on a white background. Lilly rejected the claims and said its ads are based on its SURMOUNT-5 trial, completed in 2024.<\/span><span> (Michael Siluk\/UCG\/Universal Images Group via Getty Images \/ Getty Images)<\/span><\/p>\n<\/div>\n<\/div>\n<p>&#8220;Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial. We stand firmly behind our advertising,&#8221; the spokesperson added. &#8220;It is truthful, it is transparent, and it is grounded in the most direct scientific evidence available \u2014 exactly what patients deserve. We will continue to focus on the science and defend against this lawsuit vigorously.&#8221;<\/p>\n<p>Novo is asking the court to order Lilly to remove the ads and run corrective advertising. It is also seeking damages tied to any profits Lilly may have earned from the campaign.<\/p>\n<p>The two companies are competing for control of the fast-growing obesity drug market in the U.S., which analysts say could be worth more than $100 billion by the end of the decade, according to Reuters.<\/p>\n<p><strong>TARGET BEEFS UP PROTEIN, SUPPLEMENT OFFERINGS, CAPITALIZING ON WEIGHT LOSS DRUG TREND<\/strong><\/p>\n<div class=\"inline image-ct\">\n<div class=\"m\"><picture><source media=\"(max-width: 767px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/343\/192\/weight-loss-injections-scale.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/686\/384\/weight-loss-injections-scale.jpg?ve=1&amp;tl=1 2x\"><source media=\"(min-width: 768px) and (max-width: 1023px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/672\/378\/weight-loss-injections-scale.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/1344\/756\/weight-loss-injections-scale.jpg?ve=1&amp;tl=1 2x\"><source media=\"(min-width: 1024px) and (max-width: 1279px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/931\/523\/weight-loss-injections-scale.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/1862\/1046\/weight-loss-injections-scale.jpg?ve=1&amp;tl=1 2x\"><source media=\"(min-width: 1280px)\" srcset=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/720\/405\/weight-loss-injections-scale.jpg?ve=1&amp;tl=1, https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/1440\/810\/weight-loss-injections-scale.jpg?ve=1&amp;tl=1 2x\"><img decoding=\"async\" src=\"https:\/\/a57.foxnews.com\/static.foxbusiness.com\/foxbusiness.com\/content\/uploads\/2026\/07\/931\/523\/weight-loss-injections-scale.jpg?ve=1&amp;tl=1\" alt=\"photo illustration of weight loss injection pens on a weight scale showing 176 pounds\"\/><\/source><\/source><\/source><\/source><\/picture><\/div>\n<div class=\"caption\">\n<p><span>A photo illustration shows weight-loss injection pens resting on a scale that reads 176.8 pounds. The two companies are competing for control of the fast-growing obesity drug market in the U.S.<\/span><span> (Michael Siluk\/UCG\/Universal Images Group via Getty Images \/ Getty Images)<\/span><\/p>\n<\/div>\n<\/div>\n<p>Novo said it sent Lilly a cease-and-desist letter in April but received no response.<\/p>\n<p><strong><u>GET FOX BUSINESS ON THE GO BY CLICKING HERE<\/u><\/strong><\/p>\n<p>The company also said Lilly\u2019s revised ads have been shown more than 700 million times since late April.<\/p>\n<p>Novo Nordisk could not immediately be reached by FOX Business for comment.<\/p>\n<p><i>Reuters contributed to this report.<\/i><\/p>\n<\/div>\n<p>#Novo #Nordisk #sues #Eli #Lilly #weightloss #drug #comparison #ads<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Check out what&#8217;s clickin&hellip; <\/p>\n","protected":false},"author":1,"featured_media":604,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[514,513,397,510,511,508,507,509,512],"class_list":["post-603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance-news","tag-ads","tag-comparison","tag-drug","tag-eli","tag-lilly","tag-nordisk","tag-novo","tag-sues","tag-weightloss"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads - Finance News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vaultinsider.top\/?p=603\" \/>\n<meta property=\"og:locale\" content=\"zh_CN\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads - Finance News\" \/>\n<meta property=\"og:description\" content=\"Check out what&#8217;s clickin&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.vaultinsider.top\/?p=603\" \/>\n<meta property=\"og:site_name\" content=\"Finance News\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-22T09:46:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/07\/ozempic-pen-shot.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#\\\/schema\\\/person\\\/ed40724a3e5d482ce66781a042c3c31e\"},\"headline\":\"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads\",\"datePublished\":\"2026-07-22T09:46:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603\"},\"wordCount\":586,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vaultinsider.top\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/ozempic-pen-shot.jpg\",\"keywords\":[\"ads\",\"comparison\",\"drug\",\"Eli\",\"Lilly\",\"Nordisk\",\"Novo\",\"sues\",\"weightloss\"],\"articleSection\":[\"Finance News\"],\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603\",\"url\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603\",\"name\":\"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads - Finance News\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.vaultinsider.top\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/ozempic-pen-shot.jpg\",\"datePublished\":\"2026-07-22T09:46:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#\\\/schema\\\/person\\\/ed40724a3e5d482ce66781a042c3c31e\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603#breadcrumb\"},\"inLanguage\":\"zh-Hans\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-Hans\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603#primaryimage\",\"url\":\"https:\\\/\\\/www.vaultinsider.top\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/ozempic-pen-shot.jpg\",\"contentUrl\":\"https:\\\/\\\/www.vaultinsider.top\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/ozempic-pen-shot.jpg\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/?p=603#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9875\",\"item\":\"https:\\\/\\\/www.vaultinsider.top\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#website\",\"url\":\"https:\\\/\\\/www.vaultinsider.top\\\/\",\"name\":\"Finance News\",\"description\":\"Just another Finance News site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.vaultinsider.top\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-Hans\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.vaultinsider.top\\\/#\\\/schema\\\/person\\\/ed40724a3e5d482ce66781a042c3c31e\",\"name\":\"admin\",\"url\":\"https:\\\/\\\/www.vaultinsider.top\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads - Finance News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vaultinsider.top\/?p=603","og_locale":"zh_CN","og_type":"article","og_title":"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads - Finance News","og_description":"Check out what&#8217;s clickin&hellip;","og_url":"https:\/\/www.vaultinsider.top\/?p=603","og_site_name":"Finance News","article_published_time":"2026-07-22T09:46:33+00:00","og_image":[{"width":1280,"height":720,"url":"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/07\/ozempic-pen-shot.jpg","type":"image\/jpeg"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005":"admin","\u9884\u8ba1\u9605\u8bfb\u65f6\u95f4":"3 \u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.vaultinsider.top\/?p=603#article","isPartOf":{"@id":"https:\/\/www.vaultinsider.top\/?p=603"},"author":{"name":"admin","@id":"https:\/\/www.vaultinsider.top\/#\/schema\/person\/ed40724a3e5d482ce66781a042c3c31e"},"headline":"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads","datePublished":"2026-07-22T09:46:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.vaultinsider.top\/?p=603"},"wordCount":586,"commentCount":0,"image":{"@id":"https:\/\/www.vaultinsider.top\/?p=603#primaryimage"},"thumbnailUrl":"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/07\/ozempic-pen-shot.jpg","keywords":["ads","comparison","drug","Eli","Lilly","Nordisk","Novo","sues","weightloss"],"articleSection":["Finance News"],"inLanguage":"zh-Hans","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.vaultinsider.top\/?p=603#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.vaultinsider.top\/?p=603","url":"https:\/\/www.vaultinsider.top\/?p=603","name":"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads - Finance News","isPartOf":{"@id":"https:\/\/www.vaultinsider.top\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.vaultinsider.top\/?p=603#primaryimage"},"image":{"@id":"https:\/\/www.vaultinsider.top\/?p=603#primaryimage"},"thumbnailUrl":"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/07\/ozempic-pen-shot.jpg","datePublished":"2026-07-22T09:46:33+00:00","author":{"@id":"https:\/\/www.vaultinsider.top\/#\/schema\/person\/ed40724a3e5d482ce66781a042c3c31e"},"breadcrumb":{"@id":"https:\/\/www.vaultinsider.top\/?p=603#breadcrumb"},"inLanguage":"zh-Hans","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vaultinsider.top\/?p=603"]}]},{"@type":"ImageObject","inLanguage":"zh-Hans","@id":"https:\/\/www.vaultinsider.top\/?p=603#primaryimage","url":"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/07\/ozempic-pen-shot.jpg","contentUrl":"https:\/\/www.vaultinsider.top\/wp-content\/uploads\/2026\/07\/ozempic-pen-shot.jpg","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.vaultinsider.top\/?p=603#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9875","item":"https:\/\/www.vaultinsider.top\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads"}]},{"@type":"WebSite","@id":"https:\/\/www.vaultinsider.top\/#website","url":"https:\/\/www.vaultinsider.top\/","name":"Finance News","description":"Just another Finance News site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vaultinsider.top\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-Hans"},{"@type":"Person","@id":"https:\/\/www.vaultinsider.top\/#\/schema\/person\/ed40724a3e5d482ce66781a042c3c31e","name":"admin","url":"https:\/\/www.vaultinsider.top\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/posts\/603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=603"}],"version-history":[{"count":0,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/posts\/603\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=\/wp\/v2\/media\/604"}],"wp:attachment":[{"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vaultinsider.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}